Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Equity Average (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Equity Average for 4 consecutive years, with $22.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 51.26% to $22.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.0 million, a 51.26% decrease, with the full-year FY2024 number at $50.5 million, down 16.24% from a year prior.
  • Equity Average was $22.0 million for Q3 2025 at Orchestra BioMed Holdings, up from $8.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $94.6 million in Q2 2023 to a low of $8.6 million in Q2 2025.
  • A 4-year average of $52.9 million and a median of $53.8 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 171.89% in 2023, then tumbled 83.07% in 2025.
  • Orchestra BioMed Holdings' Equity Average stood at $57.0 million in 2022, then grew by 29.6% to $73.8 million in 2023, then tumbled by 46.39% to $39.6 million in 2024, then tumbled by 44.39% to $22.0 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Equity Average are $22.0 million (Q3 2025), $8.6 million (Q2 2025), and $24.9 million (Q1 2025).